免疫检查点抑制剂相关肾炎的治疗标准
本文综述了免疫检查点抑制剂相关急性肾损伤(ICI-AKI)的病理生理、诊断与治疗进展,指出肾活检仍是诊断金标准,治疗以停用ICI、停用相关药物及糖皮质激素为主,多数患者可部分或完全恢复肾功能并允许再挑战。
要点
- ICI-AKI发生率2%-5%,急性肾小管间质性肾炎最常见。
- 可调控风险包括联用PPI、NSAIDs、抗生素及双免疫治疗。
- 一线治疗为停ICI、停相关药物并启用糖皮质激素。
核心结论
- ICI-AKI的治疗标准包括停用ICI、停用ATIN相关药物及一线糖皮质激素治疗,多数患者可获部分或完全肾功能恢复并允许ICI再挑战。
研究设计与样本
- 本文为综述,检索并汇总了关于ICI-AKI病理生理、诊断、预后及治疗标准的现有证据。
主要发现
- ICI-AKI在接受ICI治疗的患者中报告率为2%-5%,急性肾小管间质性肾炎是最常见的组织病理学病变。
- 可调控风险因素包括联用质子泵抑制剂、非甾体抗炎药和抗生素等ATIN相关药物,以及CTLA-4与PD1/PDL-1双免疫治疗。
- 及时启动治疗后多数患者可获得完全或部分肾功能恢复,从而允许ICI再挑战。
- 部分激素依赖或难治性ICI-AKI患者需要额外的保激素治疗。
关键数值与推荐
- ICI-AKI报告率2%-5%,最常见病理为急性肾小管间质性肾炎。
临床怎么用
- 怀疑ICI-AKI时应停用ICI及ATIN相关药物,并尽早启用糖皮质激素作为一线免疫抑制治疗。
- 肾活检仍是诊断首选,新兴非侵入性生物标志物尚未广泛临床验证。
局限性
- 现有证据基础主要为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last 13 years, the use of immune checkpoint inhibitor (ICI) therapy has grown remarkably, owing to their unprecedented anti-tumor efficacy in certain tumor groups. With increased use of ICIs, we are seeing immune-related adverse events (irAEs) more frequently. Renal irAEs, such as ICI-associated acute kidney injury (ICI-AKI), are reported in 2%-5% of patients treated with ICIs, with acute tubulointerstitial nephritis (ATIN) as the most common histopathologic lesion, though various forms of glomerulonephritis have also been reported. Modifiable risk factors for ICI-AKI include concurrent use of ATIN-associated drugs, like proton pump inhibitors, non-steroidal anti-inflammatory drugs and antibiotics, and dual ICI therapy with both Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) and Programmed Cell Death Protein 1 and its ligand (PD1/PDL-1) blockade. Kidney biopsies remain the diagnostic modality of choice, though several promising non-invasive biomarkers, which have not yet been broadly clinically validated have emerged. The treatment of ICI-AKI involves holding ICIs, discontinuation of ATIN-associated drugs and initiation of immunosuppression with corticosteroids as first-line therapy. With prompt treatment initiation, most patients achieve full or partial renal recovery, allowing for re-challenge with ICI. However, a subset of patients will require additional steroid-sparing therapies for corticosteroid-dependent or refractory ICI-AKI. Here we review developments in our understanding of the pathophysiology of ICI-AKI, the approach to diagnosis (with a focus on the emergence of novel diagnostic tools), prognostic factors and the current evidence for establishing treatment standards for ICI-AKI. As the evidence base remains largely retrospective, we identify questions that would benefit from future prospective studies in the diagnosis, management and prognostication of ICI-AKI.
引用
- Barbir EB, Kitchlu A, Herrmann SM, et al. Immune checkpoint inhibitor-associated nephritis-treatment standard. Nephrol Dial Transplant. 2024. PMID: 39138117. doi:10.1093/ndt/gfae184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。